Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b bridging study in healthy Japanese and Caucasian subjects
NCT03546465Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- May 2018
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV) (8 arms), sponsored by PharmaEssentia. Primary endpoints: Adverse events after single dose at Day 35 and Pharmacokinetics of ropeginterferon alfa-2b after single dose at Day 35. Started May 2018; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT03546465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546465.